Законы
Договоры
Решения
Просмотреть по юрисдикции
Order Amending Schedule 1 to the Patent Act (2014-1) (SOR/2015-154), Канада
Назад
Последняя редакция на WIPO Lex
Год версии
2014
Даты
вступление в силу:
17 июня 2015 г.
Принят:
17 июня 2015 г.
Тип текста
Имплементационные правила/положения
Предмет
Патенты (изобретения)
Примечания
The notification by Canada to the WTO under Article 63.2 of TRIPS states:
'The Order Amending Schedule 1 to the Patent Act (2014-1) adds the following names of three additional HIV/AIDS treatments to Schedule 1 to the Patent Act:
- 'efavirenz + emtricitabine + tenofovir disoproxil' in tablet form and in the specified strength of 600 mg, 200 mg, and 300 mg, respectively;
- 'emtricitabine + tenofovir disoproxil' in tablet form and in the specified strength of 200 mg, and 300 mg, respectively; and
- 'tenofovir disoproxil' in tablet form and in the specified strength of 300 mg.
The Decision of the General Council of 30 August 2003 allows WTO member countries with pharmaceutical manufacturing capacity to authorize the non-consensual use of a patented invention (i.e. compulsory licences) to manufacture and export generic versions of patented drugs and medical devices to developing countries without the capacity to manufacture the products themselves.
Canada's Access to Medicines Regime (CAMR) implements the 30 August 2003, decision by permitting the grant of 'export-only' compulsory licences to Canadian pharmaceutical manufacturers who wish to supply drugs and medical devices to countries unable to manufacture their own. The products that are eligible for export under CAMR are listed on Schedule 1 of the Patent Act. When CAMR received Royal Assent in May 2004, Schedule 1 was primarily composed of the pharmaceutical products on the World Health Organization's Model List of Essential Medicines (EML) that were patented in Canada. The EML represents the minimum medicine needs for a basic health-care system and, at the time, provided a baseline to ensure that CAMR was able to meet the basic healthcare needs of developing and least-developed countries in a clear and transparent manner.'
Имеющиеся тексты
Основной(ые) текст(ы)
Основной(ые) текст(ы)
Английский
Order Amending Schedule 1 to the Patent Act (2014-1) (SOR/2015-154)
PDF
HTML
Французский
Décret modifiant l’annexe 1 de la loi sur les brevets (2014-1) (DORS/1015-154)
PDF
HTML
Законодательство в данной области
Вносит изменения в (1 текст(s))
Вносит изменения в (1 текст(s))
Справочный индекс документа ВТО
IP/N/1/CAN/16
IP/N/1/CAN/P/12
№ в «WIPO Lex»
CA198